Osteopontin controls endothelial cell migration in vitro and in excised human valvular tissue from patients with

Paolo Poggio1, Juan B Grau, Benjamin C Field

  • 1Division of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19036, USA.

Insights

Osteopontin (OPN) drives endothelial cell activation in calcific aortic stenosis (CAS). Targeting OPN in valvular endothelial cells offers new therapeutic avenues for this prevalent cardiovascular disease.

Area of Science:

  • Cardiovascular Biology
  • Vascular Biology
  • Pathogenesis of valvular heart disease

Background:

  • Calcific aortic stenosis (CAS) involves progressive calcification of aortic valve leaflets.
  • Early CAS shares inflammatory mechanisms with atherosclerosis, including endothelial dysfunction.
  • The role of endothelial cells (ECs) in valvular degeneration is understudied.

Purpose of the Study:

  • To investigate the role of osteopontin (OPN) in regulating endothelial cell (EC) activation in CAS.
  • To explore OPN as a potential therapeutic target in valvular degeneration.

Main Methods:

  • In vitro studies of EC activation.
  • Analysis of excised human aortic valve tissue from CAS patients and controls.
  • Measurement of OPN levels in tissue and plasma.

Main Results:

  • OPN was identified as a key regulator of EC activation in CAS.
  • High OPN levels were observed in both tissue and plasma of patients with aortic valve sclerosis and stenosis.
  • Valvular ECs were characterized as a cellular target for OPN.

Conclusions:

  • Osteopontin plays a significant role in endothelial cell activation during aortic valve degeneration.
  • Targeting OPN in valvular ECs presents novel therapeutic strategies for CAS prevention and treatment.